Monitoring the tumor immune microenvironment (TIME) is vital as CD27, the receptor for CD70, is found on relevant GB TIME cell populations ​[18], suggesting the potential of co-targeting GB and its microenvironment for improved therapeutic outcomes. This evidence concerns the gene CD70 and neoplasm.